Evidence has accumulated suggesting that major depression is associated with dysfunction of inflammatory mediators. Moreover, antidepressants show an antiinflammatory action possibly related to their clinical efficacy. An improvement in psychiatric symptoms has been recently reported in patients treated with antiinflammatory drugs for other indications. These data imply that inflammation may be involved in the pathogenesis of depression and that anti-inflammatory drugs may be used as an adjunctive therapy. The aim of the present study was to evaluate the behavioural effect of the co-administration of acetylsalicylic acid (ASA, 45 mg/kg or 22.5 mg/kg) and fluoxetine (FLX, 5 mg/kg) in the chronic escape deficit model of depression. The chronic escape deficit model is based on the modified reactivity of rats to external stimuli induced by exposure to unavoidable stress and allows evaluation of the capacity of a treatment to revert the condition of escape deficit. In this model, FLX alone needs to be administered for at least 3 weeks to revert this condition. Our results show that combined treatment of fluoxetine and ASA completely reverted the condition of escape deficit by as early as 7 days, the effect being already partially present after 4 days. The effect was maintained after 14 and 21 days of treatment. ASA alone was ineffective at any time tested and the effect of fluoxetine was significant only at 21 days. These results, together with clinical data from preliminary results, suggest that ASA might accelerate the onset of action of selective serotonin reuptake inhibitor antidepressants.

Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression / Brunello, Nicoletta; Alboni, Silvia; Capone, Giacomo; Benatti, Cristina; Blom, Johanna Maria Catharina; Tascedda, Fabio; Kriwin, P; Mendlewicz, J.. - In: INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY. - ISSN 0268-1315. - STAMPA. - 21(2006), pp. 219-225.

Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression

BRUNELLO, Nicoletta;ALBONI, Silvia;CAPONE, Giacomo;BENATTI, Cristina;BLOM, Johanna Maria Catharina;TASCEDDA, Fabio;
2006

Abstract

Evidence has accumulated suggesting that major depression is associated with dysfunction of inflammatory mediators. Moreover, antidepressants show an antiinflammatory action possibly related to their clinical efficacy. An improvement in psychiatric symptoms has been recently reported in patients treated with antiinflammatory drugs for other indications. These data imply that inflammation may be involved in the pathogenesis of depression and that anti-inflammatory drugs may be used as an adjunctive therapy. The aim of the present study was to evaluate the behavioural effect of the co-administration of acetylsalicylic acid (ASA, 45 mg/kg or 22.5 mg/kg) and fluoxetine (FLX, 5 mg/kg) in the chronic escape deficit model of depression. The chronic escape deficit model is based on the modified reactivity of rats to external stimuli induced by exposure to unavoidable stress and allows evaluation of the capacity of a treatment to revert the condition of escape deficit. In this model, FLX alone needs to be administered for at least 3 weeks to revert this condition. Our results show that combined treatment of fluoxetine and ASA completely reverted the condition of escape deficit by as early as 7 days, the effect being already partially present after 4 days. The effect was maintained after 14 and 21 days of treatment. ASA alone was ineffective at any time tested and the effect of fluoxetine was significant only at 21 days. These results, together with clinical data from preliminary results, suggest that ASA might accelerate the onset of action of selective serotonin reuptake inhibitor antidepressants.
21
219
225
Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression / Brunello, Nicoletta; Alboni, Silvia; Capone, Giacomo; Benatti, Cristina; Blom, Johanna Maria Catharina; Tascedda, Fabio; Kriwin, P; Mendlewicz, J.. - In: INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY. - ISSN 0268-1315. - STAMPA. - 21(2006), pp. 219-225.
Brunello, Nicoletta; Alboni, Silvia; Capone, Giacomo; Benatti, Cristina; Blom, Johanna Maria Catharina; Tascedda, Fabio; Kriwin, P; Mendlewicz, J.
File in questo prodotto:
File Dimensione Formato  
ASA+SSRI Preclinica.pdf

non disponibili

Tipologia: Post-print dell'autore (bozza post referaggio)
Dimensione 123.58 kB
Formato Adobe PDF
123.58 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/22980
Citazioni
  • ???jsp.display-item.citation.pmc??? 28
  • Scopus 87
  • ???jsp.display-item.citation.isi??? 77
social impact